Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not sure you saw this...but some serious house cleaning took place last week.
"The Purge" occurred on 25Aug22.
https://nypost.com/2022/08/25/pharma-bro-martin-shkreli-booted-from-his-company-by-activist-revolt/
House cleaning in progress at many places Marty has touched over the years. Likely going to take a while to cleanse the SEC's palette of Marty's former presence.
After careful reconsideration, I am amending my original terming of Dr. Kelly's nickname. She should be referred to as:
Deborah "DIAMOND HANDS" Kelly, MD, FACP
And what I find interesting is that Scott Kelly's very first Form 3 with CytoDyn from when he became a director in April 2017 has Deborah Kelly coming on the radar by already owning 691,208 shares.
https://www.sec.gov/Archives/edgar/data/0001703394/000089924317010063/xslF345X03/doc3.xml
So....Deborah Kelly has been HODLING for over 5 years now and has been accumulating...
What kind of doctor is she.....let's see...
Board certified in Internal Medicine in 1998......
An Adjunct Associate Professor of Medicine at Emory School of Medicine.....
A Fellow of American College of Physicians.....
Active in the American College of Physicians-American Society of Internal Medicine, the American Medical Association, and the Royal College of Physicians....
Attended the Lovett School in Atlanta....
Graduated Cum Laude from Wake Forest University....
Attended Medical School at the Medical College of Georgia....
Completed internship and residency at Emory University School of Medicine....
That sounds like a very qualified medical doctor and someone who understands quite a bit about of why leronlimab can be beneficial in medicine...
Deborah "HODLING" Kelly, MD, FACP
And what I find interesting is that Scott Kelly's very first Form 3 with CytoDyn from when he became a director in April 2017 has Deborah Kelly coming on the radar by already owning 691,208 shares.
https://www.sec.gov/Archives/edgar/data/0001703394/000089924317010063/xslF345X03/doc3.xml
So....Deborah Kelly has been HODLING for over 5 years now and has been accumulating...
What kind of doctor is she.....let's see...
Board certified in Internal Medicine in 1998......
An Adjunct Associate Professor of Medicine at Emory School of Medicine.....
A Fellow of American College of Physicians.....
Active in the American College of Physicians-American Society of Internal Medicine, the American Medical Association, and the Royal College of Physicians....
Attended the Lovett School in Atlanta....
Graduated Cum Laude from Wake Forest University....
Attended Medical School at the Medical College of Georgia....
Completed internship and residency at Emory University School of Medicine....
That sounds like a very qualified medical doctor and someone who understands quite a bit about of why leronlimab can be beneficial in medicine...
Deborah "HODLING" Kelly, MD, FACP
Nothing conflicting about these Form 4s with the exception of basic understanding of what they mean. Everyone should probably read a little closer. Those "D" and "A" entries can be confusing as can be footnotes. These are NOT conflicting, they stand as separate Form 4 filings.
Disposed of "Old CytoDyn" shares (merged into Point NewCo Inc and renamed "New CytoDyn"). Zeroed out ALL shares in old company.
Acquired "New CytoDyn" shares in exactly the same quantity. Notice the Table I, Column 5 quantities? Matches Column 4 "A" acquired amounts - exactly.
Explanation of Responses:
1. On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock.
So, some astute post here pointed out that today's trading was so evenly balanced that it was "wash trading" that created artificial activity in the marketplace.
So, if there is an even volume on the buying and selling side that scenario might be remotely plausible.
But, can someone explain how short volume that constitutes over 50% of the day's volume contributes to "wash trading" ?
Sounds like more made up malarkey.
Hmmmm.... "everyone" says the shorts know something... But I know this much... even took an online lesson to get better smartest faster. They say 20% to 30% is a typical borrow fee for a high demand stock... But for CYDY that's so last week... We're now 5X that rate.... 130.63% per annum to be precise... And that changes daily without notice based on a 360 day year. That means right now it's costing to borrow 5X what it did last week.... For *ALL* shorts regardless when they borrowed the shares....sooo... you have to also remember that to borrow penny stocks...the $2.50 Rule....Most brokers have this rule that applies to shorting stocks under $2.50. You’ll need $2.50 of capital for each share, even if the stock is priced much lower.
So, I hope they all know this.....
..... But other than that...I just know that all I have to do is make sure my shares aren't in a margin account and no stop losses.
Eazy Peazy
Oh... And they're "connected".... Connected to what?? Connected like this?
Well, can't blame it on low volume spiking or slapping the ask. This is sustained buying and not a lot of selling it looks like. Lots of longs going with the program and holding on for the ride. Should be interesting when the good news comes out....
...oops...did I just say that out loud?
Going to sit back, pop open a cold one, review my trades, and turn on some mellow music....hmmmm....how about about Eric Clapton's remake of Danny Flower's "Tulsa Time"....
Livin' on Tulsa time
Livin' on Tulsa time
Well, you know I've been through it
When I set my watch back to it
Livin' on Tulsa Time
I heard an unsubstantiated rumor that NP had taken all those warrant conversion/sale profits from Apr 2020 and is buying his way back into the company...is it 5% or 10% that he'd have to file a 13D ?
Inquiring minds want to know....
Where is it documented that "Khazampour and Pourhassan instigated and mulholland oversaw" a "fraud scheme"?
Blowing more smoke into an already smokey situation just yields even more smoke.
Not picking up what you're putting down.....I'll let somebody else step in that.
....TIN FOIL !!! GONNA NEED MORE TIN FOIL !!!!
From sniffing around....my thought is this is probably related to the FIFE notes and that Tony Migs waited until the last minute thinking 5 Monster Ultra Fiesta Mangos could get him through Sunday night to have it delivered by this morning. Sadly it's not that simple of a process in such a short time. Plus Tony Migs has a new accounting firm looking over his shoulder....and they don't want to run afoul of any regulatory agency either......So, more time is needed to correctly "'splain tings".
https://www.eisneramper.com/convertible-debt-accounting-te-blog-0921/
I'm smelling the odors of "debt extinguishment and modifications".
The vibe I'm getting from CytoDyn...which is really difficult to read right now...is that their HIV push is really faltering. I have a suspicion any talk of HIV is going to slowly be pushed under the covers. The BLA filing looks more and more distant....if at all.
Hopefully Martin's prior influence and memory is waning and that's a good thing to keep this a clean shell company.
Ran across the latest filing in the LIFEMD, INC et al v. LAMARCO et al case. Seems that Lamarco's lawyers got a smackdown on their "Motion to Reconsider its Motion to Dismiss" - the court responded with a "DENIED" in capital letters.
https://www.pacermonitor.com/public/case/41996546/LIFEMD,_INC_et_al_v_LAMARCO_et_al
One statement that stood out of the filing was:
A motion for reconsideration addresses only factual and legal maters that the Court may have overlooked.... It is improper on a motion for reconsideration to ask the Court to rethink what [it] had already thought through - rightly or wrongly.
Apparently no one has posted all the "A lot is known" links here....because sharing is caring.
No SEC/DOJ FOIA requests have been submitted in quite a long time. So, unless the company or the SEC made some press announcement, there is still yet near ZERO details known.
So...in the absence of all those links...I'm going to just blame Canada.
Absolutely nothing is known about these investigations other than that they exist.
So, my guess is as valid as an other.....
Wouldn't it be something if the 10K details were leaking out and it has the phrase "received SEC Termination Notice" buried in there?
s3.....your move.
More than a sign of strength....think of it as a....message.
Let's see....15 pages in front for the Title, dedication, forward, table of contents, copywrite, personal notes, etc....
...then 8 pages in the back for the closing thoughts, index, etc..
That leaves 23 pages for content....
Let's say 6 chapters...each has it's own title page...that leaves 17 pages of content....
...anyone want to throw in 6 pages of pictures....or ready to "color by numbers" pictures?
A page 5.75" x 8.75 contains about 250 words (double spaced or large "easy to read type")....which means...
...about 11 pages of content ....each page has two sides....let's be generous and say they're filled up....
...comes out to 5,500 words.....
Compare that to these literary greats:
22,416 words – The Mouse and the Motorcycle – Beverly Cleary
30,644 words – Charlie and the Chocolate Factory – Roald Dahl
...or...you can look at the $26.34 cost, divide that by 46 pages.....that comes out to $0.5726 per page....each of those pages were worth more than a share of CYDY on Wednesday afternoon this week.....
Have a great weekend to all.
Wonderful....thanks for the updated info. I sit corrected.
Consider the timeline of events before attempting correlation or causation.
Kelly publishes book March 2015.
https://www.amazon.com/What-Ive-Learned-You-Patients/dp/0991274326
Kelly appointed Chief Medical Officer and Head of Business Development in April 2020.
https://www.globenewswire.com/news-release/2020/04/13/2014953/0/en/CytoDyn-Appoints-Scott-A-Kelly-M-D-as-Chief-Medical-Officer-and-Head-of-Business-Development.html
Moneycrew....let me try to do this helpfully.....
This property on July 11, 2016 was bought by Arvin Arman (hint...his middle name is "Cyrus") and his beautiful wife Melissa. Then at the later stages of closing and prior to the deed being recorded, there was an additional name added to the deed - "Arman Cyrus Trust". Then a few years went by....Then on May 6, 2022 both Arvin Arman and Melissa sold their interest in the home to the "Arman Cyrus Trust" for a sum of $670,000. This means that Arvin Arman and Melissa no longer hold any separate share of the ownership of that property - the "Arman Cyrus Trust" is full owner and controller of the property.
Now, who the members of the "Arman Cyrus Trust" are is a private matter. But lets just make it known that any child or children of Arvin and Melissa are currently minors and can't make legal decisions on their own....even if they do have a large box of crayola crayons to sign documents with....a box so large that some here would covet it for their own.....
Not sure about expecting headlines or hype. Have you seen ANY PRs from CYDY?
None about their presentations at international conferences. None about their PIPE. Not one about their new President even. Want to know what's going on.... Gotta check their 8-K fillings.
It appears to be the new paradigm post Nader.
What's so great about standards....is that there are so many to choose from....
Taking a look at this:
https://www.healthit.gov/isa/submission-clinical-research-data-fda-support-product-marketing-applications
You see that several are in "Implementation Maturity" of "Production".... but "Adoption Level" is very low. Not sure of the date of information though. Good site to peruse if data is your thing.
Also:
https://www.fda.gov/industry/fda-data-standards-advisory-board/study-data-standards-resources
https://emcifund.com/our-team/
You see that he has experience with hedge funds? Wonder how he's going to apply that knowledge to maneuvering toward bolstering stock value and uplisting.
BioVega Capital
https://www.linkedin.com/company/biovega-capital-llc/about/
Speaking of short selling...which seems to be continuing en masse up to the CC...I was reading this paper over that I found on the SEC website:
https://www.sec.gov/comments/s7-08-08/s70808-318.pdf
Very informative. And what is this...thing...they mention...."n-a-k-e-d s-h-o-r-t-i-n-g"...."naked" only shows up 121 times in the document. Must be a real thing.
Anniversaries all around today !!!
30Jun is a day that many can't forget...nor should they.
I've lost track of the number of shares sold in 100 share blocks...but it's probably up to 20K or so in the last hour. Add those to the 52+MM short shares already out...
Also watching the trades. A significant batch of 100 block shares being sold into the uptick. Looks like a crapload of shares being sold short right before the CC.
Prob not a bad decision based on previous CCs. But, then again who knows what's going to be announced...or not...during the CC.
Did anyone notice that the FTDs for the first half of June 2022 are noticeably lower than any reporting periods in the last couple of years?
Seems that Fife has stopped dumping shares into the market and that few, if any, warrant holders are "dumping" as soon as they receive them. Both good signs.
FTDs for the last year:
Soooooooo........everyone have their Q's submitted and expect to get A's back?
GLTA Long Investors
So, stock manipulation was the first thing to come to mind? Must say a lot about that... Because there was nothing mentioned in my post about that.
Meh. The short interest % to float is 7.91% now.
It's like a flaming chainsaw spinning in the air.....which end is going to get grabbed and by who.
New bi-monthly data released by FINTEL:
https://fintel.io/ss/us/cydy
Dang short interest is at an all time high. Fail To Delivers (FTD) not updated just yet, but that should be interesting also.
And there won't be anything found about Arian Colachis leaving CytoDyn employment either. Some things just don't make the front page news every day.
https://www.sec.gov/Archives/edgar/data/0001175680/000119312520220598/d923315dex1063.htm
It ain't gonna be found in there....but keep looking.
Something that everyone has failed to remember....I was waiting to see if they were going to....I've waited long enough....but....did anyone subtract the clawback of awards that were documented here?
The December 2019 Awards were forfeited effective June 4, 2021 as follows: 100% of the December 19 Awards to Michael A. Klump, Jordan G. Naydenov, and David F. Welch, Ph.D., covering 2.25 million shares, 60% of the December 2019 Award to Scott A. Kelly, M.D., covering 0.75 million shares; and 100% of the warrant to acquire 2.0 million shares issued to Nader Z. Pourhassan, Ph.D. In addition, Dr. Pourhassan forfeited vested options to purchase approximately 0.4 million shares from the December 2019 Awards. The Delaware Court held hearings on April 19 and June 4, 2021, and approved the Stipulation at the hearing on June 4, 2021.
As for mentioning a sub-clause of a plan in an SEC filing.....think of it this way...if all sub-clauses of every plan mentioned in a 10-K were included it would make reading these documents even more arduous. But, for sake of knowing that CytoDyn recognized and filed a declaration of their "Amended and Restated 2012 Equity Incentive Plan", look no further than their FY21 10-K report - Note 7 (Page 113) which states:
Note 7. Equity Awards and Warrants
The Company has one active stock-based equity plan at May 31, 2021, the CytoDyn Inc. Amended and Restated 2012 Equity Incentive Plan (the “2012 Plan”) and one stock-based equity plan that is no longer active, but under which certain prior awards remain outstanding, the CytoDyn Inc. 2004 Stock Incentive Plan (the “2004 Plan” and, together with the 2012 Plan, the “Incentive Plans”). In September 2020, the stockholders approved the CytoDyn Inc. Amended and Restated 2012 Equity Incentive Plan to increase the number of shares available for issuance from 25 million to 50 million shares, among other amendments. The total number of shares available to be issued will increase on the first day of each fiscal year in an amount equal to 1% of the total outstanding shares on the last day of the prior fiscal year, and the term of the Plan was extended for an additional 10 years to September 30, 2030. As of May 31, 2021, the Company had 15.3 million shares available for future stock-based grants under the 2012 Plan.
It's spelled out pretty clear in this 8-K (Oct 1, 2020) that everyone should have read.
https://www.sec.gov/Archives/edgar/data/1175680/000119312520261200/d935957d8k.htm
The Amended and Restated 2012 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to the Company’s employees (and the employees of any subsidiary), non-employee directors, and outside consultants or advisers. The number of shares authorized for issuance under the Amended and Restated 2012 Plan will initially be 50,000,000 shares of Common Stock (the “Share Reserve”), and the Share Reserve will automatically increase on June 1 of each calendar year, for the period beginning on June 1, 2021 and ending on (and including) June 1, 2029 (each, an “Evergreen Date”) in an amount equal to one percent (1%) of the total number of shares of Common Stock outstanding on May 31st immediately preceding the applicable Evergreen Date (the “Evergreen Increase”). The Board may act prior to the Evergreen Date of a given year to provide that there will be no Evergreen Increase for such year, or that the Evergreen Increase for such year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence.
The descriptions of the Amended and Restated 2012 Plan contained herein and in the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the Amended and Restated 2012 Plan, a copy of which is incorporated by reference to Appendix A to the Proxy Statement filed on September 1, 2020.
On June 15, 2020 and June 25, 2020, the Compensation Committee of the Board approved grants of non-qualified stock options and restricted stock unit grants to certain of the Company’s executives and directors, as described in the Proxy Statement, which grants were made under and conditional upon stockholder approval of the Amended and Restated 2012 Plan. This condition was satisfied upon approval of the stockholders of the Amended and Restated 2012 Plan at the Annual Meeting.
Oh...forgot to ask if the "Evergreen Increase" was added to those numbers. It's spelled out right in the SEC Filing for the Sep 30, 2020 " PROXY STATEMENT - 2020 ANNUAL MEETING OF STOCKHOLDERS". This agenda item was voted on and passed so it's clearly in effect...in addition to that 25,000,000 extra share increase.
https://content.edgar-online.com/ExternalLink/EDGAR/0001193125-20-237251.html?hash=9ba8ef26185f5e0f973f3b9a92a0f5bed5bbcdb1e745a2dc00265d73e847047a&dest=D32983DDEF14A_HTM#D32983DDEF14A_HTM
The amendments reflected in the Amended and Restated 2012 Plan that are subject to approval by our stockholders will increase the number of shares of common stock authorized for issuance under the 2012 Plan by 25,000,000 shares to 50,000,000, and extend the term of the 2012 Plan to September 30, 2030. The Amended and Restated 2012 Plan also includes an amendment to provide that the maximum number of shares of common stock that are available for issuance under the Plan will be increased annually on the first day of the Company’s fiscal year by an amount that is equal to 1% of the outstanding shares of all classes of the Company’s common stock on the last day of immediately preceding fiscal year (the “Evergreen Increase”). The Board will have the discretion under the Amended and Restated 2012 Plan to provide that there will be no Evergreen Increase for any fiscal year, or that the Evergreen Increase for such year will be a lesser number of shares of Common Stock than would otherwise be permitted. Other amendments reflected in the Amended and Restated 2012 Plan include a limit on nonemployee director awards, a limit on incentive stock options, clarifications regarding reversion of shares to the Amended and Restated 2012 Plan and other technical amendments.
Yes, "maff" is adding all the numbers up in front of ones eyes. But, ahhh..."analytics" is knowing what numbers are supposed to be added.